Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elena Perez

Allergy & Immunology North Palm Beach, FL Medical Doctor

NPI 1700805694 CMS profile 350134

840 US Highway 1, Suite 235, North Palm Beach, FL 33408

Open in the dashboard

General payments

$113,157

722 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$580,448 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Elena Perez of North Palm Beach, FL is reported in the CMS Open Payments database as having received $113,157 across 722 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $580,448 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23,223 153
2024 General $26,058 138
2023 General $20,147 121
2022 General $17,571 96
2021 General $8,372 81
2020 General $7,970 38
2019 General $9,816 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elena Perez
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Elena Perez were reported at $23,223. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Elena Perez Allergy & Immunology median Middle half National median
2019 $9,816 $594 $163–$1,512 $163
2020 $7,970 $426 $106–$1,233 $114
2021 $8,372 $638 $157–$1,708 $132
2022 $17,571 $790 $205–$1,961 $149
2023 $20,147 $852 $220–$2,147 $160
2024 $26,058 $865 $203–$2,267 $164
2025 $23,223 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $32,765 83 payments
  2. Grifols USA, LLC $22,544 40 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $17,182 72 payments
  4. ADMA BioManufacturing LLC $8,574 8 payments
  5. Pfizer Inc. $6,159 64 payments
  6. Shire North American Group Inc $4,855 9 payments
  7. AbbVie, Inc. $3,118 10 payments
  8. Pharming Healthcare, Inc. $3,109 20 payments
  9. Genentech USA, Inc. $2,508 12 payments
  10. ALK-Abello, Inc $1,773 26 payments
  11. Other $10,569 378 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,628 25 payments
  2. Consulting Fee $25,438 12 payments
  3. Food and Beverage $16,026 640 payments
  4. Honoraria $11,655 7 payments
  5. Travel and Lodging $7,054 23 payments
  6. Education $357 15 payments
Products named General payments · program years 2019–2025
  1. Hizentra $30,621 63 payments
  2. Xembify $23,910 38 payments
  3. HYQVIA $14,140 39 payments
  4. CUVITRU $3,838 20 payments
  5. Privigen $3,795 2 payments
  6. PRECEDEX $3,700 1 payment
  7. DEPO-TESTOSTERONE $3,700 1 payment
  8. RINVOQ $3,118 10 payments
  9. JOENJA $2,787 4 payments
  10. Xolair $2,482 11 payments
  11. Other $16,662 661 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

699

Median for Allergy/ Immunology: 449

Drug cost

$782,896

Median for Allergy/ Immunology: $169,700

Branded share of claims

38.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 39 $269,075
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 11 $166,184
Dupixent Syringe Dupilumab Brand 41 $152,289
Dupixent Pen Dupilumab Brand 21 $75,892
Xolair Omalizumab Brand 12 $56,166
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $18,337
Cromolyn Sodium Generic 12 $10,805
Breo Ellipta Fluticasone/Vilanterol Brand 17 $10,737
Symbicort Budesonide/Formoterol Fumarate Brand 13 $6,143
Epinephrine Generic 33 $5,952

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$246,306

Of which drugs: $134,099

Medicare patients

419

Average age 74

Services billed

9,280

302 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 61%
Ischemic heart disease 37%
Osteoporosis 31%
COPD 27%
Depression 25%
Diabetes 21%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg J1561 Office 16 1,620 $62,653
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 Office 13 1,420 $50,533

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xembify
$6,998 — —
Hizentra
$6,185 — —
Privigen
$1,118 — —
DUPIXENT
$769 62 —
FASENRA
$242 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

722 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record